Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
38 studies found for:    " December 15, 2010":" January 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" December 15, 2010":" January 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting A Trial With TMC278-TIDP6-C222 for Continued TMC278 Access in Patients Infected With Human Immunodeficiency Virus-1
Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
2 Active, not recruiting Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Condition: HIV Dementia
Intervention: Drug: Atorvastatin
3 Unknown  Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection
Conditions: HIV Infections;   Liver Toxicity;   Hepatitis Co-infection
Intervention:
4 Active, not recruiting
Has Results
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: Dolutegravir;   Drug: Atripla;   Drug: Abacavir/Lamivudine;   Drug: Abacavir/Lamivudine Placebo;   Drug: Dolutegravir placebo;   Drug: Atripla placebo
5 Completed Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
Condition: HIV Infection
Intervention: Biological: Fluzone®
6 Unknown  Risk Taking Behaviour in MSM and the Denial of Sexually Transmitted Diseases and HIV
Conditions: MSM;   HIV Infections;   Risky Behaviors
Intervention:
7 Withdrawn A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572;   Drug: GSK2248761
8 Completed Study in Healthy Volunteers of the Safety and Metabolism of Different Doses of the Anti-HIV Drug TMC278LA.
Condition: HIV Infection
Intervention: Drug: TMC278LA
9 Completed The Intensive Pharmacokinetics Sub-study of Encore1 (ENCORE1-PK)
Condition: HIV Infection
Intervention: Drug: Efavirenz
10 Completed The Efavirenz (EFV) Central Nervous System Exposure Sub-study of Encore1
Condition: HIV Infection
Intervention: Drug: Efavirenz
11 Unknown  Ethnicity Data in HIV Positive Men Who Have Sex With Men
Condition: HIV Infections
Intervention:
12 Completed TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir
Condition: HIV Infections
Interventions: Drug: TMC278;   Drug: Raltegravir
13 Completed Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines
Condition: HIV Infections
Interventions: Biological: Adjuvanted GSK investigational HIV vaccine formulation 1;   Biological: Adjuvanted GSK investigational HIV vaccine formulation 2;   Biological: Ad35 investigational HIV vaccine;   Biological: Placebo (saline)
14 Completed Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose
Condition: HIV Infection
Interventions: Drug: Aprepitant;   Drug: Aprepitant placebo
15 Completed Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults
Condition: HIV Infections
Interventions: Biological: Profectus HIV MAG pDNA vaccine;   Biological: IL-12;   Other: Placebo
16 Completed Acquired Epidermodysplasia Verruciformis (EV) Syndrome in HIV-infected Pediatric Patients
Conditions: Flat Warts (Diagnosis);   HIV Infections
Intervention: Drug: Glycolic acid
17 Withdrawn A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: 200mg [14C]- GSK2248761
18 Withdrawn Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.
Conditions: HIV Infections;   Healthy
Interventions: Drug: BI 224436;   Drug: Placebo
19 Completed Recovery Management Intervention in China
Conditions: Methadone;   HIV Infections
Intervention: Behavioral: Recovery management
20 Completed
Has Results
Effects of Growth Hormone Releasing Hormone in HIV
Conditions: HIV;   HIV Lipodystrophy
Interventions: Drug: tesamorelin;   Drug: placebo

   Previous Page Studies Shown (1-20) Next Page (21-38) Show next page of results    Last Page
Indicates status has not been verified in more than two years